Modulation of doxorubicin-induced cardiac dysfunction in dominant-negative p38α mitogen-activated protein kinase mice.

[1]  Anthony J. Muslin,et al.  Dominant-negative p38alpha mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. , 2009, American journal of physiology. Heart and circulatory physiology.

[2]  Anthony J. Muslin,et al.  14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy. , 2008, Biochemical pharmacology.

[3]  M. Picard,et al.  Disruption of Nitric Oxide Synthase 3 Protects Against the Cardiac Injury, Dysfunction, and Mortality Induced by Doxorubicin , 2007, Circulation.

[4]  G. Takemura,et al.  Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. , 2007, Progress in cardiovascular diseases.

[5]  J. Zweier,et al.  Heat shock protects cardiac cells from doxorubicin-induced toxicity by activating p38 MAPK and phosphorylation of small heat shock protein 27. , 2006, American journal of physiology. Heart and circulatory physiology.

[6]  R. Novak,et al.  DNA damage is an early event in doxorubicin-induced cardiac myocyte death. , 2006, American journal of physiology. Heart and circulatory physiology.

[7]  C. Tschöpe,et al.  Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus , 2006, Diabetologia.

[8]  K. Hirata,et al.  Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. , 2006, Atherosclerosis.

[9]  E. Levin,et al.  Estrogen Prevents Cardiomyocyte Apoptosis through Inhibition of Reactive Oxygen Species and Differential Regulation of p38 Kinase Isoforms* , 2006, Journal of Biological Chemistry.

[10]  W. Manning,et al.  Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure. , 2005, American journal of physiology. Heart and circulatory physiology.

[11]  O. Mian,et al.  Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice , 2005, Molecular and Cellular Biochemistry.

[12]  P. Singal,et al.  Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. , 2005, American journal of physiology. Heart and circulatory physiology.

[13]  I. Kubota,et al.  Modulation of Doxorubicin-Induced Cardiac Dysfunction in Toll-Like Receptor-2–Knockout Mice , 2004, Circulation.

[14]  S. Lancel,et al.  Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells , 2004, Oncogene.

[15]  J. Saklatvala.  The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. , 2004, Current opinion in pharmacology.

[16]  J. Blenis,et al.  ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions , 2004, Microbiology and Molecular Biology Reviews.

[17]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[18]  A. Nishiyama,et al.  ROS During the Acute Phase of Ang II Hypertension Participates in Cardiovascular MAPK Activation But Not Vasoconstriction , 2004, Hypertension.

[19]  S. Aslam,et al.  Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. , 2003, Journal of the American Society of Nephrology : JASN.

[20]  R. Reeves,et al.  Protection from doxorubicin-induced cardiac toxicity in mice with a null allele of carbonyl reductase 1. , 2003, Cancer research.

[21]  Attila Kovacs,et al.  The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. , 2003, The Journal of clinical investigation.

[22]  S. Kalivendi,et al.  Paradoxical effects of metalloporphyrins on doxorubicin-induced apoptosis: scavenging of reactive oxygen species versus induction of heme oxygenase-1. , 2002, Free radical biology & medicine.

[23]  H. Masutani,et al.  Overexpression of Thioredoxin-1 in Transgenic Mice Attenuates Adriamycin-Induced Cardiotoxicity , 2002, Circulation.

[24]  I. Komuro,et al.  Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. , 2002, Hypertension research : official journal of the Japanese Society of Hypertension.

[25]  C. Steenbergen.  The role of p38 mitogen-activated protein kinase in myocardial ischemia/reperfusion injury; relationship to ischemic preconditioning , 2002, Basic Research in Cardiology.

[26]  J. Joseph,et al.  Doxorubicin-induced Apoptosis Is Associated with Increased Transcription of Endothelial Nitric-oxide Synthase , 2001, The Journal of Biological Chemistry.

[27]  Y. Taya,et al.  Osmotic Shock Induces G1 Arrest through p53 Phosphorylation at Ser33 by Activated p38MAPK without Phosphorylation at Ser15 and Ser20 * , 2001, The Journal of Biological Chemistry.

[28]  D. Fitzgerald,et al.  Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. , 2001, The Journal of clinical investigation.

[29]  G. Sandusky,et al.  Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK alpha is the predominant isoform expressed in human heart. , 2001, Journal of molecular and cellular cardiology.

[30]  R C Chaubey,et al.  Gamma ray induced DNA damage in human and mouse leucocytes measured by SCGE-Pro: a software developed for automated image analysis and data processing for Comet assay. , 2001, Mutation research.

[31]  J. Joseph,et al.  Doxorubicin-induced Apoptosis in Endothelial Cells and Cardiomyocytes Is Ameliorated by Nitrone Spin Traps and Ebselen , 2000, The Journal of Biological Chemistry.

[32]  P. Singal,et al.  Adriamycin-Induced Early Changes in Myocardial Antioxidant Enzymes and Their Modulation by Probucol , 2000, Circulation.

[33]  D. Cohen,et al.  MAPK signaling and the kidney. , 2000, American journal of physiology. Renal physiology.

[34]  S. Groshen,et al.  Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  M. Karin,et al.  Requirement for p38α in Erythropoietin Expression A Role for Stress Kinases in Erythropoiesis , 2000, Cell.

[36]  J. Bauer,et al.  Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. , 2000, The Journal of pharmacology and experimental therapeutics.

[37]  O. Inanami,et al.  Roles of p38 MAPK, PKC and PI3‐K in the signaling pathways of NADPH oxidase activation and phagocytosis in bovine polymorphonuclear leukocytes , 2000, FEBS letters.

[38]  M. Okabe,et al.  Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Burger-Kentischer,et al.  Possible involvement of heat shock protein 25 in the angiotensin II‐induced glomerular mesangial cell contraction via p38 MAP kinase , 1999, Journal of cellular physiology.

[40]  A. Segal,et al.  Activation of the neutrophil NADPH oxidase is inhibited by SB 203580, a specific inhibitor of SAPK2/p38. , 1999, Biochemical and biophysical research communications.

[41]  Weiya Ma,et al.  p38 Kinase Mediates UV-induced Phosphorylation of p53 Protein at Serine 389* , 1999, The Journal of Biological Chemistry.

[42]  P. Singal,et al.  Doxorubicin-induced cardiomyopathy. , 1998, The New England journal of medicine.

[43]  B. Davidson,et al.  Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. , 1998, Circulation research.

[44]  R. Alexander,et al.  p38 Mitogen-activated Protein Kinase Is a Critical Component of the Redox-sensitive Signaling Pathways Activated by Angiotensin II , 1998, The Journal of Biological Chemistry.

[45]  J Ross,et al.  Cardiac Muscle Cell Hypertrophy and Apoptosis Induced by Distinct Members of the p38 Mitogen-activated Protein Kinase Family* , 1998, The Journal of Biological Chemistry.

[46]  Y. J. Kang,et al.  Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. , 1997, The Journal of clinical investigation.

[47]  D. S. St. Clair,et al.  The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. , 1996, The Journal of clinical investigation.

[48]  Y. J. Kang,et al.  Suppression of Doxorubicin Cardiotoxicity by Overexpression of Catalase in the Heart of Transgenic Mice (*) , 1996, The Journal of Biological Chemistry.

[49]  Carmen Birchmeier,et al.  Multiple essential functions of neuregulin in development , 1995, Nature.

[50]  R. Mueller,et al.  Doxorubicin toxicity in perfused rat heart. Decreased cell death at low oxygen tension. , 1991, Circulation research.

[51]  B. Kalyanaraman,et al.  An electron spin resonance study of the reduction of peroxides by anthracycline semiquinones. , 1984, Biochimica et biophysica acta.

[52]  L. Wold,et al.  Doxorubicin induces cardiomyocyte dysfunction via a p38 MAP kinase-dependent oxidative stress mechanism. , 2005, Cancer detection and prevention.

[53]  J. Zweier,et al.  Viswanathan Natarajan Cells Regulation by Map Kinases in Human Lung Endothelial Hyperoxia-induced Nad(p)h Oxidase Activation And , 2002 .

[54]  J. Bonventre,et al.  Growth factors and mitogen-activated protein kinases. , 1998, Hypertension.

[55]  E. Monti,et al.  Free radical-dependent DNA lesions are involved in the delayed cardiotoxicity induced by adriamycin in the rat. , 1995, Anticancer research.